Clinical Evaluation of Florbetapir F 18 (18F-AV-45)

PHASE2CompletedINTERVENTIONAL
Enrollment

1,768

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

May 3, 2017

Study Completion Date

May 3, 2017

Conditions
Alzheimer DiseaseMild Cognitive ImpairmentNeurodegenerative Diseases
Interventions
DRUG

Florbetapir F 18

370 MBq (10 mCi)

Trial Locations (26)

19107

Jefferson, Philadelphia

University of Pennsylvania, Philadelphia

21287

Johns Hopkins University, Baltimore

27104

Wake Forest University, Winston-Salem

27710

Duke University, Durham

32254

Mayo Clinic Jacksonville, Jacksonville

33140

Mt. Sinai Medical Center, Miami Beach

37232

Vanderbilt, Nashville

37920

University of Tennessee, Knoxville

39216

University of Mississippi Medical Center, Jackson

60611

Northwestern University, Chicago

63110

Washington University School of Medicine, St Louis

66160

University of Kansas, Kansas City

75231

UTSW, Dallas

75235

UTSW, Dallas

75390

UTSW, Dallas

85006

Banner Health, Phoenix

85351

Banner Sun Health Research Institute, Sun City

90033

University of Southern California, Los Angeles

92697

UC Irvine, Irvine

92868

UC Irvine, Orange

94121

UC San Francisco, San Francisco

94143

UC San Francisco Memory Center, San Francisco

95618

UC Davis, Davis

02114

Massachusetts General Hospital, Boston

02906

Butler Hospital, Providence

Sponsors
All Listed Sponsors
lead

Avid Radiopharmaceuticals

INDUSTRY